|
|
View Clinical Trial (Medical Research Study)
|
A Clinical Study of PHY906 as a Modulator of CPT-11 in Patients With Metastatic Colorectal Cancer - NCT00730158-06516 (Clinical Trial 235159)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy235159.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
West Haven |
|
State:
|
|
CT |
| Zip Code: |
|
06516 |
| Conditions: |
|
Colorectal Neoplasms |
| Purpose: |
|
PHY906 is an oral form of a spray dried aqueous extract composed of four main herbs, which
have been used in the Orient for nearly 2000 years for a variety of GI symptoms including
diarrhea and nausea/vomiting. Extensive pre-clinical research has been done with Chinese
herbal medicine, and studies have documented significant anticancer activity in combination
with various cytotoxic agents including CPT-11, which is a semi-synthetic derivative of the
natural alkaloid camptothecin and belongs to the class of topoisomerase I inhibitors. The
proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as an
adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer. Our
rationale for the therapeutic use of PHY906 is its potential activity in reducing
chemotherapy-induced toxicity, especially diarrhea.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Patients must have histologically confirmed malignancy that is metastatic or
unresectable and for which standard curative or palliative measures do not exist or
are no longer effective (Phase I Part).
- Patients with histologically confirmed metastatic colorectal cancer, who failed with
prior two different chemotherapy regimens (Phase II Part).
- At least one evaluable lesion. Lesions must be evaluated by computerized tomography
(CT), magnetic resonance imaging (MRI), or PET scan (Phase I Part).
- At least one measurable lesion by CT or MRI of ≥ 20 mm (if conventional CT scan) or ≥
10 mm (if spiral CT scan) (Phase II part)
- Karnofsky Performance Status ≥ 60%
- Must be ≥18 years of age.
- Expected survival of at least 3 months for phase I part, and at least 6 months for
phase II part.
- Women of child-bearing potential (i.e., women who are pre-menopausal or not
surgically sterile) must use acceptable contraceptive methods (abstinence,
intrauterine device [IUD], oral contraceptive or double barrier device), and must
have a negative serum or urine pregnancy test within 1 week prior to beginning
treatment on this trial. Nursing patients are excluded. Sexually active men must also
use acceptable contraceptive methods. Pregnant and nursing patients are excluded
because the effects of the combination of PHY906 and CPT-11 on a fetus or nursing
child are unknown.
- Must be able and willing to give written informed consent.
- Patients must have the following clinical laboratory values:
ANC count ≥ 1,500/ mm3. Platelets ≥ 100,000/ mm3. Serum creatinine ≤ 2x upper limit of
normal. Total bilirubin < 1.5x upper limit of normal. Serum calcium < 12.0 mg/dl. Alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x the upper limit of normal
(≤ 5.0 x ULN is acceptable if liver has tumor involvement) Prothrombin Time (PT),
activated partial thromboplastin time (aPTT) and INR ≤ 1.5 x ULN or in the therapeutic
range if on anticoagulation Hemoglobin ≥ 9 gm/dl (may be corrected by transfusion).
Exclusion Criteria:
- Symptomatic brain metastasis.
- Serious concomitant systemic disorders (e.g., active infection) that, in the opinion
of the investigator, would compromise the safety of the patient or compromise the
patient's ability to complete the study.
- Unwilling or unable to follow protocol requirements or to give informed consent.
- No treatment with cytotoxic or biologic agents within the 4 weeks prior to beginning
treatment on this study (6 weeks for mitomycin or nitrosoureas). At least 4 weeks
must have elapsed from any prior surgery, radiation, hormonal or other drug therapy
for their cancer.
- Known HIV positivity, as safety in this patient population has not been assessed.
- Presence of metastatic disease that, in the opinion of investigators, would require
palliative treatment within 4 weeks of enrollment.
- Altered mental status precluding understanding of the informed consent process and/or
completion of the necessary studies.
- Pregnant or breast-feeding women.
- Men and women of childbearing age and potential, who are not willing to use effective
contraception.
- Major surgery within the last 4 weeks.
- Patients taking concurrent medications of any kind which are strong inducers or
inhibitors of CYP3A4. Patients receiving any of the following will be excluded:
ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone,
nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, phenytoin,
carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort. |
|
|
|
| Study is available at: |
|
VACT Cancer Center
West Haven, CT 06516
United States
Primary Contact:
Michal Rose, M.D.
Phone: 203-937-3421
Secondary Contact:
Lois Ravage-Mass, RN
Email: lois.ravage-mass@yale.edu
Phone: 203-785-4991 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|